References
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–30
- Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218: 583–92
- Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: A 25-year review. Br J Surg 1989; 76: 535–40
- Macdonald JS. Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol 2005; 90: 166–70
- Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41
- Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587–91
- Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–8
- Mantell BS. Radiotherapy for dysphagia due to gastric carcinoma. Br J Surg 1982; 69: 69–70
- Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys 2007; 67: 385–8
- Harvey JA, Bessell JR, Beller E, Thomas J, Gotley DC, Burmeister BH, et al. Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. Dis Esophagus 2004; 17: 260–5
- Burmeister BH, Denham JW, O'Brien M, Jamieson GG, Gill PG, Devitt P, et al. Combined modality therapy for esophageal carcinoma: Preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995; 32: 997–1006